Viking Global Shows Abeona Therapeutics Stake ~ market folly

Tuesday, October 3, 2017

Viking Global Shows Abeona Therapeutics Stake

Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding shares of Abeona Therapeutics (ABEO.  Per the filing, Viking now owns 5.6% of the company with over 2.23 million shares.

This is a newly disclosed equity stake for the firm and the filing was made due to portfolio activity on September 22nd.

For more on this hedge fund, we've posted some other recent portfolio activity from Viking Global here.

Per Google Finance, Abeona Therapeutics is a "clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process."

blog comments powered by Disqus